Announcement • Apr 28
Dar Al Dawa Development and Investment Co. Ltd. announces Annual dividend Dar Al Dawa Development and Investment Co. Ltd. announced Annual dividend of JOD 0.0300 per share, ex-date on April 28, 2026 and record date on April 27, 2026. Announcement • Apr 03
Dar Al Dawa Development and Investment Co. Ltd., Annual General Meeting, Apr 27, 2026 Dar Al Dawa Development and Investment Co. Ltd., Annual General Meeting, Apr 27, 2026. Location: amman Jordan Board Change • Mar 30
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 12 non-independent directors. Director Fadi Nassar was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Nov 11
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risk Market cap is less than US$100m (د.أ39.6m market cap, or US$55.8m). Reported Earnings • Aug 02
Second quarter 2025 earnings released: EPS: د.أ0.033 (vs د.أ0.02 in 2Q 2024) Second quarter 2025 results: EPS: د.أ0.033 (up from د.أ0.02 in 2Q 2024). Revenue: د.أ19.1m (down 6.5% from 2Q 2024). Net income: د.أ1.15m (up 66% from 2Q 2024). Profit margin: 6.0% (up from 3.4% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 04
First quarter 2025 earnings released: EPS: د.أ0.16 (vs د.أ0.013 in 1Q 2024) First quarter 2025 results: EPS: د.أ0.16 (up from د.أ0.013 in 1Q 2024). Revenue: د.أ18.2m (up 10% from 1Q 2024). Net income: د.أ573.8k (up 21% from 1Q 2024). Profit margin: 3.2% (up from 2.9% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Apr 03
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 12 non-independent directors. Representative Director Taghreed Al-Shunnar was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 19
Dar Al Dawa Development and Investment Co. Ltd., Annual General Meeting, Apr 24, 2025 Dar Al Dawa Development and Investment Co. Ltd., Annual General Meeting, Apr 24, 2025. Location: amman Jordan Reported Earnings • Feb 19
Full year 2024 earnings released: EPS: د.أ0.10 (vs د.أ0.09 in FY 2023) Full year 2024 results: EPS: د.أ0.10 (up from د.أ0.09 in FY 2023). Revenue: د.أ81.2m (up 8.4% from FY 2023). Net income: د.أ3.61m (up 14% from FY 2023). Profit margin: 4.4% (up from 4.2% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 03
Third quarter 2024 earnings released: EPS: د.أ0.035 (vs د.أ0.028 in 3Q 2023) Third quarter 2024 results: EPS: د.أ0.035 (up from د.أ0.028 in 3Q 2023). Revenue: د.أ21.6m (up 1.9% from 3Q 2023). Net income: د.أ1.23m (up 26% from 3Q 2023). Profit margin: 5.7% (up from 4.6% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. New Risk • Aug 17
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (د.أ45.5m market cap, or US$64.2m). Reported Earnings • May 02
First quarter 2024 earnings released First quarter 2024 results: Revenue: د.أ13.6m (down 11% from 1Q 2023). Net income: د.أ410.5k (down 12% from 1Q 2023). Profit margin: 3.0% (in line with 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. New Risk • Apr 08
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (د.أ46.6m market cap, or US$65.7m). Reported Earnings • Apr 03
Full year 2023 earnings released Full year 2023 results: Revenue: د.أ74.9m (up 24% from FY 2022). Net income: د.أ3.16m (up 36% from FY 2022). Profit margin: 4.2% (up from 3.8% in FY 2022). The increase in margin was driven by higher revenue. Reported Earnings • Nov 05
Third quarter 2023 earnings released: EPS: د.أ0.028 (vs د.أ0.032 in 3Q 2022) Third quarter 2023 results: EPS: د.أ0.028. Revenue: د.أ21.2m (up 27% from 3Q 2022). Net income: د.أ980.8k (up 18% from 3Q 2022). Profit margin: 4.6% (down from 4.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 03
Second quarter 2023 earnings released: EPS: د.أ0.022 (vs د.أ0.013 in 2Q 2022) Second quarter 2023 results: EPS: د.أ0.022 (up from د.أ0.013 in 2Q 2022). Revenue: د.أ18.9m (up 37% from 2Q 2022). Net income: د.أ763.7k (up 69% from 2Q 2022). Profit margin: 4.0% (up from 3.3% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to د.أ1.25, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 41% over the past three years. Reported Earnings • May 06
First quarter 2023 earnings released: EPS: د.أ0.013 (vs د.أ0.008 in 1Q 2022) First quarter 2023 results: EPS: د.أ0.013 (up from د.أ0.008 in 1Q 2022). Revenue: د.أ15.4m (up 27% from 1Q 2022). Net income: د.أ466.5k (up 63% from 1Q 2022). Profit margin: 3.0% (up from 2.4% in 1Q 2022). The increase in margin was driven by higher revenue. Reported Earnings • Feb 15
Full year 2022 earnings released: EPS: د.أ0.062 (vs د.أ0.031 in FY 2021) Full year 2022 results: EPS: د.أ0.062 (up from د.أ0.031 in FY 2021). Revenue: د.أ60.4m (up 17% from FY 2021). Net income: د.أ2.17m (up 107% from FY 2021). Profit margin: 3.6% (up from 2.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Chairman of the Board Akram Abdul Hasan Jerab was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 03
Third quarter 2022 earnings released: EPS: د.أ0.023 (vs د.أ0.009 in 3Q 2021) Third quarter 2022 results: EPS: د.أ0.023 (up from د.أ0.009 in 3Q 2021). Revenue: د.أ16.8m (up 26% from 3Q 2021). Net income: د.أ828.7k (up 165% from 3Q 2021). Profit margin: 4.9% (up from 2.3% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improved over the past week After last week's 15% share price gain to د.أ1.13, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 17% over the past three years. Reported Earnings • May 02
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: د.أ0.008 (up from د.أ0.003 in 1Q 2021). Revenue: د.أ12.1m (up 7.8% from 1Q 2021). Net income: د.أ286.3k (up 129% from 1Q 2021). Profit margin: 2.4% (up from 1.1% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Chairman of the Board Akram Abdul Hasan Jerab was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Apr 03
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: EPS: د.أ0.031 (down from د.أ0.35 in FY 2020). Revenue: د.أ51.8m (down 2.6% from FY 2020). Net income: د.أ1.05m (down 88% from FY 2020). Profit margin: 2.0% (down from 16% in FY 2020). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 03
New 90-day high: د.أ1.20 The company is up 19% from its price of د.أ1.01 on 05 August 2020. The Jordanian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. Is New 90 Day High Low • Sep 30
New 90-day high: د.أ1.16 The company is up 18% from its price of د.أ0.98 on 02 July 2020. The Jordanian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.